IMUGENE CHART. TA only, page-37072

Sentiment the meaning of,'
Mental feeling; emotion, noun. an attitude toward something; regard; opinion. a mental feeling; emotion: a sentiment of pity'.

Sentiment is all powerful when it comes to share trading, we all know the meaning but very few of us can determine what is driving sentiment at any particular time.

Sometimes it can be influenced by external factors such as Regulatory authorities, political decisions and conflict, at other times it could be viewed as internal factors such as financial, trial failures, loss of key personnel, etc. , or a combination of all the above.

We can all vouch for the influence from internet forum contributors on both the negative and the positive impacts.

However the biggest influences can be and should backed up by facts, unfortunately many of us in the modern world have the memory of a Gnat,( A gnat has an attention span of zero and it has no memory. It responds to stimulus rather like a machine.
However, before you feel smug, the attention span of humans has reduced from around 12 seconds in 2000 to only 8 seconds in 2015.)

Therefore when we have a vacuum of information, as in no data updates, no news of BP interest and no certainty of funds to drive ongoing trials we have the perfect storm developing in which all types of speculation can abound.

And this is what is driving SENTIMENT.

How do we as Shareholders of this company work against this sentiment, well as difficult as it might seem we need to take stock of where we were when all momentum stopped, this would be IMO around the time we purchased Azer-cel.

We had a heap of money in the bank, a very manageable remuneration and a couple of promising drugs in the clinic.

Now rightly or wrongly Management saw great promise in the licensing of Azer-cel and they most likely were told that the facility and staff came with the agreement, this is where they got in over their heads, and I believe opened them up to being played by traders and others, and also made raising more funds difficult as the sums were not adding up.

We know now after recent trial data that Azer-cel is showing great promise and with 4 out of 7 patients having complete responses, following up to 5 prior lines of treatment so with the sale of the facility with staff attached we are now back to square one and can at least limit further dilution of the company.

Our biggest threat now with the Shareprice in the gutter is a hostile takeover, I’m hoping that management have the capacity to see something like this off until such time that we are closer to an FDA approval or the out licensing of one or more of our products.

The gift of INDs and Fast Track will assist us in expediting these treatments if data continues to show promising results.

Let’s hope that we can turn Sentiment around and that new shareholders that have bought in at more reasonable prices will tell all their wealthy friends to get on board the IMU train, I'm certainly keen to see what's at the end of the track.

DYOR opinion only